Second COVID-19 vax ‘needs to be timely’ in RA

Antibody titres are much lower in patients on DMARDs, researchers find
Reuters Health

Researchers from Switzerland report that the timing of the second dose of mRNA vaccine for COVID-19 appears to have a key role to play in patients with rheumatoid arthritis (RA) on disease-modifying anti-rheumatic drugs (DMARDs), on the basis of results from their small study.

The authors write that the kinetics of the vaccine-induced humoral immune response differ between patients with RA who are taking DMARDs and healthy individuals.